Spermosens (SPERM) Q2 2025 earnings summary

Executive summary

• Achieved a pivotal milestone with strong clinical results validating the diagnostic value of JUNO-Checked, supporting its potential as a game changer in the infertility market.

• Clinical study showed statistically significant correlation between JUNO Score and IVF fertilization rates, highlighting limitations of conventional semen analysis.

• Increased interest from established ART market players, supporting ongoing licensing and partnership strategies.

• Fully exercised TO5 warrants and strategic investments secured financial resources for continued development.

Financial highlights

• Net sales for Q2 and H1 2025 were SEK 0 thousand, unchanged from the previous year.

• Operating loss for Q2 2025 was SEK -2,662 thousand, compared to SEK -2,055 thousand in Q2 2024.

• H1 2025 operating loss totaled SEK -4,725 thousand, similar to SEK -4,659 thousand in H1 2024.

• Cash and cash equivalents at period end were SEK 11,817 thousand, up from SEK 2,959 thousand a year earlier.

• Equity at period end was SEK 36,879 thousand, compared to SEK 24,132 thousand in the prior year.

Outlook and guidance

• Focus remains on advancing JUNO-Checked toward market launch, with resources allocated to developing a third-generation system for higher throughput and integration into routine laboratory practice.

• Increased business development activity and partner interest following clinical validation.